Written answers

Tuesday, 28 May 2024

Department of Health

Medicinal Products

Photo of David CullinaneDavid Cullinane (Waterford, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

479. To ask the Minister for Health if consideration has been given to providing access to the medical cannabis access programme for cerebral palsy; if so, the outcome of that consideration; the list of conditions that were or are being considered for addition; the status of those considerations; and if he will make a statement on the matter. [23983/24]

Photo of Stephen DonnellyStephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

When I took the decision for a clinical review of the MCAP in order to examine whether sufficient evidence existed to expand the scope of the programme no specific conditions requiring the use of cannabis products for use under MCAP were considered above any others. The first stage of the process - the gathering and synthesis of evidence emanated from treatment or trials of any condition and the process has continued along these same lines. Evidence of this is available from the Health Research Board's publication "The efficacy and safety of medicinal cannabis in adult populations: An evidence review", as published in January of this year. www.hrb.ie/publications/publication/the-efficacy-and-safety-of-medicinal-cannabis-in-adult-populations-an-evidence-review/returnPage/1/

A clinical review of the evidence, to ascertain if there is necessity to broaden the scope of the programme, will be commencing shortly.

Comments

No comments

Log in or join to post a public comment.